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Daptomycin-nonsusceptible (DNS) Staphylococcus aureus is found in difficult-to-treat infections, and the optimal therapy is
unknown. We investigated the activity of high-dose (HD) daptomycin plus trimethoprim-sulfamethoxazole de-escalated to HD
daptomycin or trimethoprim-sulfamethoxazole against 4 clinical DNS methicillin-resistant S. aureus (MRSA) isolates in an in
vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations (109 CFU/g). Simulated regimens in-
cluded HD daptomycin at 10 mg/kg/day for 14 days, trimethoprim-sulfamethoxazole at 160/800 mg every 12 h for 14 days, HD
daptomycin plus trimethoprim-sulfamethoxazole for 14 days, and the combination for 7 days de-escalated to HD daptomycin
for 7 days and de-escalated to trimethoprim-sulfamethoxazole for 7 days. Differences in CFU/g (at 168 and 336 h) were evaluated
by analysis of variance (ANOVA) with a Tukey’s post hoc test. Daptomycin MICs were 4 g/ml (SA H9749-1, vancomycin-inter-
mediate Staphylococcus aureus; R6212, heteroresistant vancomycin-intermediate Staphylococcus aureus) and 2 g/ml (R5599
and R5563). Trimethoprim-sulfamethoxazole MICs were <0.06/1.19 g/ml. HD daptomycin plus trimethoprim-sulfamethoxa-
zole displayed rapid bactericidal activity against SA H9749-1 (at 7 h) and R6212 (at 6 h) and bactericidal activity against R5599
(at 72 h) and R5563 (at 36 h). A >8 log10 CFU/g decrease was observed with HD daptomycin plus trimethoprim-sulfamethoxa-
zole against all strains (at 48 to 144 h), which was maintained with de-escalation to HD daptomycin or trimethoprim-sulfame-
thoxazole at 336 h. The combination for 14 days and the combination for 7 days de-escalated to HD daptomycin or trim-
ethoprim-sulfamethoxazole was significantly better than daptomycin monotherapy (P < 0.05) and trimethoprim-
sulfamethoxazole monotherapy (P < 0.05) at 168 and 336 h. Combination therapy followed by de-escalation offers a novel
bactericidal therapeutic alternative for high-inoculum, serious DNS MRSA infections.
Daptomycin is a concentration-dependent cyclic lipopeptideantibiotic with activity against Gram-positive organisms that
exerts its bactericidal activity by binding to and inserting into
bacterial membranes, thereby leading to rapid membrane depo-
larization and deregulation of several cell functions, such as DNA,
RNA, and protein synthesis (9, 18, 31). Daptomycin susceptibility
in Staphylococcus aureus is defined as a MIC of 1 g/ml, and any
strains with a MIC of 1 g/ml are referred to as daptomycin
nonsusceptible (DNS) (8). The rate of DNS S. aureus in North
America over the last several years is low (0.01 to 0.1%), with no
trend in increasing MIC values (7, 25, 29, 30). The development of
DNS in S. aureus is due to a series of incremental changes in the
cell membrane and wall due to changes in gene expression or the
development of genetic mutations that increase the MIC and
eventually lead to DNS strains (13–16, 23, 27, 33, 37). This vari-
ability in genetic alterations leading to DNS may explain why dap-
tomycin retains some activity against these strains. We have pre-
viously demonstrated that daptomycin at simulated doses of 6
mg/kg/day and 10 mg/kg/day in an in vitro pharmacokinetic/
pharmacodynamic (PK/PD) model maintained bactericidal activ-
ity against some DNS S. aureus strains, although time to bacteri-
cidal activity was increased and regrowth often occurred (26, 28).
The development of DNS in S. aureus has occurred mainly in
patients with complicated infections, such as osteomyelitis, septic
arthritis, or endocarditis (6, 32). Optimal therapy for these types
of infections requires agents with bactericidal activity to ensure a
rapid reduction of the bacterial burden and the highest probability
of clinical cure. Unfortunately, clinicians commonly turn to bac-
teriostatic agents such as linezolid, tigecycline, trimethoprim-sul-
famethoxazole, clindamycin, and tetracyclines when they encoun-
ter a DNS S. aureus infection. Clinical data on successful treatment
of infections caused by DNS S. aureus is limited to a few case
reports (32). The optimal therapy for the treatment of compli-
cated infections caused by DNS S. aureus in which a bactericidal
regimen is desired is currently unknown. Utilizing the activity
daptomycin maintains against DNS strains, we have previously
demonstrated a novel combination of daptomycin at 6 mg/kg/
day, and trimethoprim-sulfamethoxazole was rapidly bactericidal
against two DNS S. aureus strains, including one that was also a
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heteroresistant vancomycin-intermediate Staphylococcus aureus
(hVISA) strain, in a 3-day in vitro PK/PD model of simulated
endocardial vegetations (SEV) (35). Since our first study utilized
only two strains, a relatively short duration of treatment, and the
standard dose of daptomycin (6 mg/kg/day), further data are
needed to characterize the potential benefit of this novel antibiotic
combination. As daptomycin therapy is often salvage therapy after
vancomycin and the potential exists under these circumstances to
influence daptomycin’s activity, it would be prudent to utilize
high-dose daptomycin (10 mg/kg) and therefore examine this
dose in combination with trimethoprim-sulfamethoxazole over a
prolonged period of time in the in vitro PK/PD SEV model. Addi-
tionally, since the types of infections caused by DNS S. aureus
strains often require therapy lasting several weeks, the optimal
length of combination therapy would need to be evaluated. The
objective of the study was to examine the combination of high-
dose daptomycin with trimethoprim-sulfamethoxazole for 14
days or de-escalated to daptomycin or trimethoprim-sulfame-
thoxazole at day 7 against 4 clinical DNS methicillin-resistant
Staphylococcus aureus (MRSA) strains in a 14-day in vitro PK/PD
model with SEV.
MATERIALS AND METHODS
Bacterial strains. A total of four clinical DNS MRSA isolates were evalu-
ated: SA H9749-1 (VISA isolate recovered from a patient with osteomy-
elitis at St. Joseph’s Hospital Center, Syracuse, NY), R6212 (hVISA isolate
from Detroit Medical Center), R5599 (MRSA blood isolate from Albany
Medical Center), and R5563 (MRSA blood isolate).
Antimicrobials. Daptomycin was provided by Cubist Pharmaceuti-
cals. Trimethoprim-sulfamethoxazole was commercially purchased from
Sigma-Aldrich Co. (St. Louis, MO). Stock solutions of each antimicrobial
were prepared daily per Clinical and Laboratory Standards Institute rec-
ommendations (8).
Media. Mueller-Hinton II broth (Difco, Detroit, MI) with 25 mg/liter
calcium and 12.5 mg/liter magnesium (MHBII) was used for MIC testing
and in vitro PK/PD models, except for those with daptomycin. Due to the
dependency of daptomycin on calcium for antimicrobial activity, Muel-
ler-Hinton II broth was supplemented (SMHBII) to 50 mg/liter calcium
for MIC testing and to 75 mg/liter calcium (equivalent to 50 mg/liter of
calcium in the presence of albumin) for in vitro PK/PD models (19).
Colony counts were determined using tryptic soy agar (TSA; Difco, De-
troit, MI) plates. The development of resistance to daptomycin and tri-
methoprim-sulfamethoxazole was evaluated using either MHBII and agar
(Bacto; Difco, Detroit, MI) supplemented with 50 mg/liter of calcium
(due to the dependency of daptomycin on calcium for antimicrobial ac-
tivity) or brain heart infusion agar (BHIA; Difco, Detroit, MI) plates con-
taining the respective antimicrobial at a concentration of three times
the MIC.
Susceptibility testing. MICs of study antimicrobial agents were deter-
mined by broth microdilution at 106 CFU/ml according to Clinical and
Laboratory Standards Institute guidelines (8). All were incubated at 37°C
for 18 to 24 h.
SEVs. Organism stocks were prepared by inoculating three TSA plates
for overnight growth at 37°C. Organisms were swabbed from the growth
plates into 5-ml test tubes containing SMHBII, resulting in a concentra-
tion of approximately 1010 CFU/ml. Simulated endocardial vegetations
(SEVs) were prepared in 1.5 ml siliconized Eppendorf tubes by mixing
0.05 ml of organism suspension (final inoculum, 109 CFU/g), 0.5 ml of
human cryoprecipitated antihemophilic factor from volunteer donors
(American Red Cross, Detroit, MI), and 0.025 ml of platelet suspension
(platelets mixed with normal saline; 250,000 to 500,000 platelets per clot;
American Red Cross, Detroit, MI). Bovine thrombin (0.05 ml; 5,000
U/ml; GenTrac, Inc., Middleton, WI) was added to each tube after inser-
tion of a sterile monofilament line into the mixture. The resultant simu-
lated vegetations were then removed from the Eppendorf tubes with a
sterile disposable plastic needle (Becton, Dickinson, Sparks, MD) and
introduced into the model. This methodology results in SEVs consisting
of approximately 3 to 3.5 g/dl of albumin and 6.8 to 7.4 g/dl of total
protein (1).
In vitro PK/PD model. A two-compartment in vitro model consisting
of a 250-ml glass apparatus with ports where the SEVs were suspended was
utilized for all simulations. The apparatus was prefilled with media, and
antibiotics were administered as boluses over a 336-h time period into the
central compartment via an injection port. The model apparatus was
placed in a 37°C water bath throughout the procedure, and a magnetic stir
bar was placed in the media for thorough mixing of the drug in the model.
Fresh medium was continuously supplied and removed from the com-
partment along with the drug via a peristaltic pump (Masterflex; Cole-
Parmer Instrument Company, Chicago, IL) set to simulate the half-lives
of the antibiotics. Simulated antibiotic regimens were daptomycin at 10
mg/kg every 24 h (estimated total peak and half-life [T1/2], 141.1 mg/liter
and 8 h, respectively) for 14 days and trimethoprim-sulfamethoxazole at
160/800 mg every 12 h (2.4/100 mg/liter, 10/10 h) for 14 days (4, 20).
Combination simulated antibiotic regimens included daptomycin plus
trimethoprim-sulfamethoxazole for 14 days, daptomycin plus trim-
ethoprim-sulfamethoxazole for 7 days followed by daptomycin for 7 days,
and daptomycin plus trimethoprim-sulfamethoxazole for 7 days followed
by trimethoprim-sulfamethoxazole for 7 days. The elimination rate for
the combination models was set for the antibiotic with the shorter half-
life, and the antibiotic with the longer half-life was supplemented into the
second chamber (5). All simulated drug regimens were performed in du-
plicate to ensure reproducibility.
Pharmacodynamic analysis. Two simulated endocardial vegetations
were removed from each model at 0, 4, 8, 24, 32, 48, 72, 96, 120, 144, 168,
176, 192, 200, 216, 240, 264, 288, 312, and 336 h. The SEVs were homog-
enized and diluted in cold saline to be plated onto TSA plates. To mini-
mize antibiotic carryover, all samples were diluted at least 10-fold before
plating. If the drug concentration at the anticipated dilution was within 1
tube dilution of the MIC or higher, then vacuum filtration (100-l sam-
ples washed through a 0.45-m filter with normal saline) was used to
avoid antibiotic carryover. Plates were then incubated at 37°C for 24 h, at
which time a colony count was performed. These methods have a lower
limit of detection of 1 log10 CFU/g. The total reduction in log10 CFU/g
over 336 h was determined by plotting time-kill curves based on the num-
ber of remaining organisms over the 336-h time period. Bactericidal ac-
tivity (99.9% kill) was defined as a 3-log10 CFU/g reduction in colony
count from the initial inoculum. Bacteriostatic activity was defined as a
3-log10 CFU/g reduction in colony count from the initial inoculum,
while inactive was defined as no observed reductions from the initial in-
ocula. The time to achieve a 99.9% bacterial load reduction was deter-
mined by linear regression (if r2  0.95) or by visual inspection.
Pharmacokinetic analysis. Pharmacokinetic samples were obtained,
through the injection port of each model (duplicate samples) at 0, 4, 8, 24,
32, 48, 72, 96, 120, 144, 168, 176, 192, 200, 216, 240, 264, 288, 312, and 336
h for verification of target antibiotic concentrations. All samples were
stored at 70°C until they were ready for analysis. Daptomycin concen-
trations were determined by a previously validated bioassay (Micrococcus
luteus ATCC 9341; antibiotic assay medium 1; standards of 200, 100, and
50 mg/liter) (2). Blank 1/4-in disks were placed on a preswabbed plate and
spotted with 10 l of the standard or sample. For trimethoprim, we uti-
lized a bioassay (S. aureus R1867; Mueller-Hinton Agar; standards of 40,
20, and 10 mg/liter) (35). Briefly, 1/4-in holes were punched in the pre-
swabbed agar plate and filled with 50 l of the standards or samples. This
assay has a lower limit of detection of 10 mg/liter and a between-day
percent coefficient of variation of 7.15. A separate trimethoprim model
was run at 10 times the targeted concentration to utilize this assay due to
detection limits. For sulfamethoxazole, we utilized a bioassay (S. aureus
R1867; Mueller-Hinton agar; standards of 125, 75, and 50 mg/liter) (35).
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Briefly, 1/4-in holes were punched in the preswabbed agar plate and filled
with 50 l of the standard or sample, which contained 6 mg/liter of tri-
methoprim. This assay had a between-day coefficient of variation of 9.0%.
A separate model was run for sulfamethoxazole to evaluate pharmacoki-
netic parameters. Each standard was tested in duplicate. Plates were incu-
bated for 18 to 24 h at 37°C, at which time the zone sizes were measured
using a protocol reader (Microbiology International, Frederick, MD). The
half-lives, areas under the concentration-time curve from 0 to 24 h
(AUC
0-24 h
), AUC24 h/MIC, and peak concentrations of the antibiotics were
determined by the trapezoidal method utilizing PK Analyst software (ver-
sion 1.10; MicroMath Scientific Software, Salt Lake City, UT).
Resistance. Development of resistance was evaluated at 168 and 336 h.
One hundred-l samples from each time point were plated on BHIA or
SMHBII agar plates containing three times the drug MIC to assess the
development of resistance. Plates were examined for growth after 48 h of
incubation at 37°C.
Statistical analysis. Changes in CFU/g at 168 and 336 h were com-
pared by two-way analysis of variance with Tukey’s post hoc test. A P
value of 0.05 was considered significant. All statistical analyses were
performed using SPSS statistical software (Release 20.0; SPSS, Inc.,
Chicago, IL).
RESULTS
MIC values for the evaluated isolates are displayed in Table 1. All
isolates are DNS and trimethoprim-sulfamethoxazole susceptible.
Isolate SA H9749-1 is a VISA strain (vancomycin MIC of 8 to 16
g/ml via broth microdilution), and isolate R6212 was an hVISA
strain (ratio with Mu3 of 0.96 by modified population analysis).
Observed pharmacokinetic parameters (total peak and T1/2) were
145.8 to 146.1 mg/liter (targeted at 141.1 mg/liter) and 6.9 to 8.2 h
(targeted at 8 h) for daptomycin, 23.6 to 25.1 mg/liter (targeted at
24 [2.4 mg/liter  10]) and 9.3 to 10.1 h (targeted at 10 h) for
trimethoprim, and 98 to 104.8 mg/liter (targeted at 100 mg/liter)
and 9.6 to 10.2 h (targeted at 10 h) for sulfamethoxazole.
The quantitative changes in the log10 CFU/g for the tested reg-
imens against the four tested strains are displayed in Fig. 1A to D
and Table 2. Against all four tested strains, the novel combination
of daptomycin plus trimethoprim-sulfamethoxazole for the first 7
days produced a greater than 8 log10 CFU/g reduction by 168 h (7
days), and this decrease was sustained to 336 h (14 days) for the
combination regimen and de-escalation to daptomycin at 10
mg/kg or trimethoprim-sulfamethoxazole. The combination of
daptomycin plus trimethoprim-sulfamethoxazole produced rapid
and sustained bactericidal activity against the VISA strain SA
H9749-1 (7 h) and the hVISA strain R6212 (6 h). Time to sus-
tained bactericidal activity with the combination of daptomycin
plus trimethoprim-sulfamethoxazole was longer for MRSA R5599
(72 h) and MRSA R5563 (36 h). Trimethoprim-sulfamethoxazole
was not bactericidal against any tested strains. Daptomycin alone
displayed sustained bactericidal activity against two of the tested
strains at 14 h (VISA strain SA H9749-1) and 32 h (MRSA strain
R5563). Daptomycin plus trimethoprim-sulfamethoxazole, the
combination de-escalated to daptomycin, and the combination
de-escalated to trimethoprim-sulfamethoxazole were significantly
better than daptomycin (P  0.05), trimethoprim-sulfamethoxazole
(P  0.05), and the growth control (P  0.05) at 168 and 336 h. No
organisms with MIC values of 3 the initial MIC or greater were
recovered for either drug at 168 or 336 h.
DISCUSSION
As stated previously, the optimal therapy for DNS MRSA infec-
tions is complicated, as the majority are deep-seated, high-inocu-
lum infections requiring long-term therapy, and evidence is lim-
ited (6, 21). Optimal therapy would be cost-effective, have
minimal side effects, and display bactericidal activity, particularly
for endocarditis, in which failure due to bacteriostatic antibiotics
is well documented (12, 24). Daptomycin nonsusceptibility in S.
aureus is a complicated phenotype that can arise from multiple
genetic alterations and is variable among strains. The mechanism
of DNS in S. aureus is due to the additive effects of many potential
changes found in some, but not all, strains. One common mech-
anism is increased cell surface charge, thus repulsing the positively
charged daptomycin-calcium complex. This process may occur
via translocation of positively charged phospholipids to the outer
side of the cytoplasmic membrane, lysinylation of membrane
phosphatidylglycerol, and/or increased D-alanylation of cell wall
teichoic acids (10, 11, 14, 17, 23, 36). Increased cell wall thickness,
alterations in membrane proteins, and changes in membrane flu-
idity are also often associated with DNS S. aureus (10, 16, 22).
Since DNS in S. aureus is due to the cumulative affect of many of
these changes and is not due to one change conferring high-level
nonsusceptibility, it is rational that daptomycin retains activity
against some of these strains. Previous results from our laboratory
have shown that daptomycin maintains variable levels of activity
against DNS S. aureus (26, 28). The results of the current study
were consistent with daptomycin demonstrating delayed bacteri-
cidal activity against VISA SA H9749-1 (14 h) and MRSA R5563
(32 h) and a lack of sustained bactericidal activity against the other
two strains. The enhancement of this remaining activity in com-
bination with trimethoprim-sulfamethoxazole was examined in
this study as a potential combination therapy for DNS MRSA
strains.
In this study, we evaluated the activity of daptomycin plus
trimethoprim-sulfamethoxazole against four clinical DNS MRSA
strains, including one VISA and one hVISA strain, under high-
inoculum conditions (9.5 log10 CFU/g). The combination was
able to produce a substantial reduction of greater than 8 log10
CFU/g against all four strains tested. Additionally, for 168 to 336 h
(days 7 to 14), the combination, de-escalation to daptomycin, and
de-escalation to trimethoprim-sulfamethoxazole were able to sus-
tain this decrease in colony counts and keep viable colony counts
close to detection limits. Based on these in vitro data, the combi-
nation of daptomycin plus trimethoprim-sulfamethoxazole pro-
vides a possible treatment option for high-inoculum infections
with DNS MRSA, including those in which bactericidal therapy
would be optimal. The high susceptibility of S. aureus to tri-
methoprim-sulfamethoxazole of greater than 98% among clinical
isolates in the United States supports the potential wide use of this
combination (30). Additionally, these in vitro data support the
de-escalation to either daptomycin or trimethoprim-sulfame-
thoxazole. This ability to de-escalate while maintaining regimen




SA H9749-1 4 0.03/0.6 8–16
R6212 4 0.06/1.19 2
R5599 2 0.06/1.19 1
R5563 2 0.03/0.6 2
a DAP, daptomycin; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin.
DAP plus TMP/SMX against MRSA in an In Vitro SEV Model
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activity provides clinicians with the option to stop one agent if
necessary due to cost (daptomycin), side effects (increased serum
creatinine with trimethoprim-sulfamethoxazole or increased cre-
atine phosphokinase with daptomycin), or regimen complexity.
Interestingly, time to bactericidal activity was shorter for the VISA
(SA H9749-1) and hVISA (R6212) strains than for the two tested
MRSA strains R5599 and R5563. While the mechanism for this
increased activity is unknown, it is possible the mechanism of
FIG 1 Activity of tested regimens in the in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Closed squares, daptomycin
plus trimethoprim-sulfamethoxazole (DSXT) for 14 days; open triangle, DSXT for 7 days followed by SXT for 7 days; open circles, DSXT for 7 days followed by
daptomycin at 10 mg/kg/day (D10) for 7 days; closed circles, D10 for 14 days; closed triangles, SXT for 14 days; open squares, growth control.
TABLE 2 Activity of tested regimens in the in vitro pharmacokinetic/pharmacodynamic modela
Isolate
Time (h) to 99.9% kill
Change in log10 CFU/g at:
168 h 336 h
DAP SXT DSXT DAP SXT DAP SXT DSXT DAP SXT DAP SXT DSXT DAP SXT
SA H 14 NA 7 7 7 5.35 2.65 8.34 8.34 8.34 5.11 2.54 8.84 7.94 8.75
R6212 NA NA 6 6 6 2.98 0.67 8.33 8.33 8.33 1.44 1.65 8.81 8.81 8.49
R5599 336 NA 72 72 72 1.48 0.58 8.93 8.93 8.93 3.7 1.31 8.93 8.93 8.93
R5563 32 NA 36 36 36 4.47 0.42 8.21 8.21 8.21 4.43 0.98 8.88 8.69 8.88
a Time to 99.9% kill refers to the time to bactericidal activity sustained at 336 h. DAP, daptomycin at 10 mg/kg/day for 14 days; SXT, trimethoprim-sulfamethoxazole for 14 days;
DSXT, daptomycin plus trimethoprim-sulfamethoxazole for 14 days; DAP, daptomycin plus trimethoprim-sulfamethoxazole for 7 days followed by daptomycin for 7 days;
SXT, daptomycin plus trimethoprim-sulfamethoxazole for 7 days followed by trimethoprim-sulfamethoxazole; SA H, SA H9749-1; NA, not applicable.
Steed et al.
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synergy for daptomycin plus trimethoprim-sulfamethoxazole is
more potent against these isolates.
Preliminary clinical data have been favorable regarding this
combination to treat osteomyelitis caused by S. aureus with re-
duced susceptibility to both vancomycin and daptomycin (34).
The first patient received high-dose daptomycin and tri-
methoprim-sulfamethoxazole as salvage therapy for vertebral os-
teomyelitis with SA H9749-1 (vancomycin MIC of 8 to 16 and
daptomycin MIC of 4 g/ml) and achieved a clinical cure. The
second patient received daptomycin plus trimethoprim-sulfame-
thoxazole as salvage therapy for chronic vertebral osteomyelitis
with concurrent prolonged bacteremia from SA F31774 (vanco-
mycin MIC of 4 and daptomycin MIC of 4 g/ml). This combi-
nation cleared the bacteremia in 48 h but was stopped after 7 days
due to an increase in serum creatinine. The patient’s regimen was
then changed to daptomycin plus rifampin. Unfortunately, the
patient subsequently deteriorated for a week on this combination
before dying.
While this study was strengthened by its use of four DNS
MRSA strains with various levels of susceptibility to vancomycin
and its 14-day study duration, it still has some limitations. While
the treatment duration in this in vitro model of simulated endo-
cardial vegetations was 14 days, this is still shorter than the 4 to 6
weeks typically required to treat infections such as staphylococcal
endocarditis (3). Based on data for the second patient reported
above, more than 1 week of combination therapy may be required
in vivo before de-escalation. In conclusion, the combination of
daptomycin plus trimethoprim-sulfamethoxazole produced sus-
tained bactericidal activity against four DNS MRSA strains, in-
cluding one VISA strain and one hVISA strain, and this inoculum
decrease was maintained when de-escalating to daptomycin or
trimethoprim-sulfamethoxazole. Further clinical research exam-
ining this combination and the optimal time to de-escalate is war-
ranted.
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